CD38
ENSG00000004468
Target class
Enzyme
Chromosome
4
Approved drugs
2
Clinical candidates (approved and in development)
5
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- No
- Other names
- cADPR1
- Target name
- CD38
- Gene name
- CD38 molecule
- Gene symbol
- CD38
- Protein name
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (EC 3.2.2.-) (EC 3.2.2.6) (2'-phospho-ADP-ribosyl cyclase) (2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase) (EC 2.4.99.20) (2'-phospho-cyclic-ADP-ribose transferase) (ADP-ribosyl cyclase 1) (ADPRC 1) (Cyclic ADP-ribose hydrolase 1) (cADPR hydrolase 1) (T10) (CD antigen CD38)
- Gene biotype
- Protein coding
- Gene family
- CD molecules
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 43
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 38.48
- Tissue specificity (Gini)
- 0.555
- Tissue specificity (tau)
- 0.925
- KEGG gene identifiers
- hsa:952
- Reactome pathways
- R-HSA-196807
- Protein interaction confidence
- 0.833032
- Protein interaction partners
- 94
- End position
- 15853232
- Start position
- 15778275
- Chromosome
- 4
- Strand
- Forward
- Cell surface . Cell membrane
- Single-pass type II membrane protein. Note=Localizes in membrane lipid domains. .
- Plasma membrane
- PubMed 2319135
- PubMed 16293598
- PubMed 8253715
- Tissue specificity (tau)
- 0.925435
- Expression inequality (Gini)
- 0.555413
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 38.48
- Spleen
- 25.8
- Brain - Caudate (basal ganglia)
- 7.29
- Small Intestine - Terminal Ileum
- 6.51
- Lung
- 6.09
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes38.48
- Spleen25.8
- Brain - Caudate (basal ganglia)7.29
- Small Intestine - Terminal Ileum6.51
- Lung6.09
- Prostate5.74
- Brain - Putamen (basal ganglia)5.38
- Brain - Nucleus accumbens (basal ganglia)4.71
- Artery - Coronary4.63
- Thyroid4.33
- Nerve - Tibial4.04
- Brain - Substantia nigra3.84
- Adipose - Subcutaneous3.84
- Adipose - Visceral (Omentum)3.53
- Pituitary3.52
- Brain - Hypothalamus3.37
- Whole Blood3.2
- Muscle - Skeletal3.11
- Adrenal Gland3.1
- Heart - Atrial Appendage2.98
- Brain - Hippocampus2.82
- Fallopian Tube2.81
- Brain - Anterior cingulate cortex (BA24)2.8
- Brain - Frontal Cortex (BA9)2.51
- Brain - Cortex2.39
And 29 more, listed on the interactive page.
- GO:0009410
- GO:0030890
- GO:0042110
- GO:0043066
- GO:0045892
- GO:0045893
- GO:0050853
- GO:0097190
- GO:1901847
- GO:0005886
- GO:0009986
- GO:0016020
- GO:0070062
- GO:0038023
- GO:0061809
regulation of gene expression
Studies
- cell-based: BSK_SAg_CD38, is one of 10 assay component(s) measured or calculated from the BSK_SAg assay. It is designed to make measurements of enzyme-linked immunosorbent assay, a form of binding reporter, as detected with fluorescence intensity signals by Enzyme-linked immunosorbent assay technology.
Biological samples
- umbilical vein endothelium and peripheral blood mononuclear cells, primary cell co-culture
Evidence source
Related records
Trials (588)
- "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
- A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia
- A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
- A Clinical Study to Evaluate SM17 for Atopic Dermatitis
- A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
- A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
- A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
- A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
- A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- A Open-Label Phase in Participants With Multiple Myeloma
- A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants
- A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
- A Phase 1b Study of WU-NK-101 in Combination With Cetuximab
Drugs (5)
- Daratumumab Lymphocyte differentiation antigen CD38 inhibitor
- Felzartamab Lymphocyte differentiation antigen CD38 inhibitor
- Humax-IL15 Lymphocyte differentiation antigen CD38 inhibitor
- Isatuximab Lymphocyte differentiation antigen CD38 inhibitor
- Mezagitamab Lymphocyte differentiation antigen CD38 binding agent